GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.57 is considered Overvalued compared with the five-year average of 33.07. The fair price of GeneDx Holdings Corp (WGS) is between 51.04 to 70.17 according to relative valuation method. Compared to the current price of 74.20 USD , GeneDx Holdings Corp By Overvalued By 5.75%.

Relative Value

Fair Zone

51.04-70.17

Current Price：74.20

5.75%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is GeneDx Holdings Corp (WGS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

GeneDx Holdings Corp (WGS) has a current Price-to-Book (P/B) ratio of 13.08. Compared to its 3-year average P/B ratio of 5.56, the current P/B ratio is approximately 135.07% higher. Relative to its 5-year average P/B ratio of 3.74, the current P/B ratio is about 249.67% higher. GeneDx Holdings Corp (WGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.40%. Compared to its 3-year average FCF yield of -89.15%, the current FCF yield is approximately -100.45% lower. Relative to its 5-year average FCF yield of -73.02%, the current FCF yield is about -100.55% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for WGS competitors is 2.16, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS.O) exhibits a P/S ratio of 7.57, which is 250% above the industry average. Given its robust revenue growth of 26.50%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of WGS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of WGS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is WGS currently overvalued or undervalued?

What is GeneDx Holdings Corp (WGS) fair value?

WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of GeneDx Holdings Corp (WGS) is between 51.04 to 70.17 according to relative valuation method.

How does WGS's valuation metrics compare to the industry average?

The average P/S ratio for WGS's competitors is 2.16, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of 7.57, which is 250.00% above the industry average. Given its robust revenue growth of 26.50%, this premium appears sustainable.

What is the current P/B ratio for GeneDx Holdings Corp (WGS) as of Mar 03 2026?

As of Mar 03 2026, GeneDx Holdings Corp (WGS) has a P/B ratio of 13.08. This indicates that the market values WGS at 13.08 times its book value.

What is the current FCF Yield for GeneDx Holdings Corp (WGS) as of Mar 03 2026?

As of Mar 03 2026, GeneDx Holdings Corp (WGS) has a FCF Yield of 0.40%. This means that for every dollar of GeneDx Holdings Corp's market capitalization, the company generates 0.40 cents in free cash flow.

What is the current Forward P/E ratio for GeneDx Holdings Corp (WGS) as of Mar 03 2026?

As of Mar 03 2026, GeneDx Holdings Corp (WGS) has a Forward P/E ratio of 445.30. This means the market is willing to pay $445.30 for every dollar of GeneDx Holdings Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for GeneDx Holdings Corp (WGS) as of Mar 03 2026?

As of Mar 03 2026, GeneDx Holdings Corp (WGS) has a Forward P/S ratio of 7.57. This means the market is valuing WGS at $7.57 for every dollar of expected revenue over the next 12 months.

WGS Valuation